Business Context and Reporting Period
Company: Mangoceuticals, Inc. (MGRX)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2025
Business Overview: The Company operates a telemedicine platform focusing on men's wellness products (ED, hair loss, testosterone, weight management) under brands such as Mango, Grow, Mojo, and Slim. It also markets FDA-approved oral testosterone (Prime) and holds patents for respiratory illness prevention technology. The Company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 | Balance Sheet (Sept 30, 2025) |
|---|---|---|---|
| Revenues | $84,246 | $361,661 | - |
| Net Loss (Attributable to Common Stockholders) | $(7,912,218) | $(18,755,427) | - |
| Loss Per Share (Basic & Diluted) | $(0.69) | $(2.16) | - |
| Cash and Cash Equivalents | - | - | $481,281 |
| Total Assets | - | - | $16,531,802 |
| Total Liabilities | - | - | $804,275 |
| Working Capital | - | - | $(206,052) Deficit |
| Accumulated Deficit | - | - | $(37,877,913) |
Key Expense Drivers: Stock-based compensation was the primary driver of expenses, totaling $6.6 million for the quarter and $10.8 million for the nine-month period. Operating expenses for the nine months ended September 30, 2025, were $17.9 million.
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased 37% year-over-year for the quarter ($84k vs. $133k) and 29% for the nine-month period ($362k vs. $511k). Management attributes this to transition issues migrating from the original telemedicine platform to a new telehealth platform.
- Increased Net Loss: Net loss increased significantly due to a surge in stock-based compensation ($6.6M in Q3 2025 vs. $0.6M in Q3 2024) and higher general and administrative expenses related to intellectual property acquisitions and legal fees.
- Balance Sheet Strength: Cash increased from $58,653 at year-end 2024 to $481,281 at September 30, 2025, driven by financing activities including the sale of common stock, preferred stock, and warrant exercises.
- Intangible Assets: Significant additions to intangible assets (patents and licenses) occurred, though a $4.75 million asset related to the Navy Wharf agreement was rescinded and removed in July 2025.
Guidance, Outlook, Risks, and Unusual Items
Going Concern: The Company has raised substantial doubt about its ability to continue as a going concern. With an accumulated deficit of $37.9 million and a working capital deficit, management states that current capital resources are insufficient to fund operations for the next 12 months without additional financing.
Outlook and Funding: The Company plans to raise additional capital through equity or debt offerings, which may result in significant dilution. It is also evaluating strategic alternatives, including mergers or acquisitions.
Unusual Items and Transactions:
- Rescinded Agreements: The Company rescinded Master Distribution Agreements with Navy Wharf (July 2025) and Smokeless Technology (May 2025), cancelling previously issued shares and removing associated intangible assets.
- Related Party Transactions: Significant transactions involve the CEO, Jacob D. Cohen, including loans (Tiger Cub Trust), equity issuances to a subsidiary (Mango & Peaches) giving him 75.2% voting control, and related-party pharmacy services (Epiq Scripts).
- Legal Settlements: Settled a false advertising lawsuit with Eli Lilly for $20,000 cash and agreed to cease marketing specific tirzepatide products. Settled a dispute with 1800 Diagonal Lending via stock issuance.
- Digital Assets: Facilitated the conversion of approximately $500,000 in digital assets to fiat currency during the quarter to support liquidity.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline and certainty of the next capital raise given the explicit "Going Concern" warning and current cash burn rate.
- Revenue Recovery: Confirm the status of the new telehealth platform migration and whether revenue declines are expected to reverse in Q4 2025.
- Dilution Impact: Assess the dilution from recent and potential future issuances of Series B Preferred Stock, common stock, and warrants, particularly given the low conversion prices ($1.50).
- Related Party Control: Review the implications of the CEO's 75.2% voting control over the Mango & Peaches subsidiary and the concentration of related-party transactions.
- Intangible Asset Valuation: Scrutinize the remaining value of acquired patents (Intramont, Greenfield) and the commercialization timeline for the respiratory technology, given the history of rescinded IP deals.